Back to mobile site

Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)

November 7, 2024 10:43 AM EST Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login